Skip to main content

Affinity Asset Advisors, LLC

Position in ASND — Ascendis Pharma A/S

CIK 1773195 NEW YORK, NY

Position in ASND

as of Mar 31, 2026 · filed May 14, 2026
Position Value
$21,729,350
+$15,332,150 QoQ
Shares Held
95,000
+216.7% QoQ
Ownership
0.145%
of shares outstanding
% of Portfolio
1.32%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Dec 2020
14 quarters on record
Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in ASND Over Time

Shares Held

Position Value (USD)

Derivatives in ASND

reported options exposure · as of Mar 31, 2021
CallValue
$0
CallShares
0
PutValue
$2,577,600
PutShares
20,000

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

Affinity Asset Advisors, LLC holds $1,518,254,571 across 81 Biotechnology names. ASND ranks #25 (1.4% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in ASND

Export CSV
15 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $21,729,350 95,000
2025-12-31 $6,397,200 30,000
2023-12-31 $2,519,000 20,000
2023-09-30 $4,344,896 46,400
2023-06-30 $5,155,080 57,760
2023-03-31 $4,288,800 40,000
2022-12-31 $8,670,863 70,997
2022-09-30 $10,326,000 100,000
2022-06-30 $11,628,087 125,087
2022-03-31 $14,083,200 120,000
2021-09-30 $5,723,694 35,910
2021-06-30 $2,631,000 20,000
2021-03-31 $2,577,600 20,000
2021-03-31 $2,577,600 20,000
2020-12-31 $1,667,800 10,000